50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
5 Game-Changing Cheap Stocks (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Sell every Stock except ONE (Ad)
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
Sell every Stock except ONE (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
5 Game-Changing Cheap Stocks (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Sell every Stock except ONE (Ad)
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
Sell every Stock except ONE (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
5 Game-Changing Cheap Stocks (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Sell every Stock except ONE (Ad)
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
Sell every Stock except ONE (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
5 Game-Changing Cheap Stocks (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Sell every Stock except ONE (Ad)
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
Sell every Stock except ONE (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
NASDAQ:APVO

Aptevo Therapeutics - APVO Stock Forecast, Price & News

$3.12
-0.17 (-5.17%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.11
$3.30
50-Day Range
$3.12
$4.59
52-Week Range
$3.03
$22.08
Volume
65,743 shs
Average Volume
41,954 shs
Market Capitalization
$15.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.50

Aptevo Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
685.3% Upside
$24.50 Price Target
Short Interest
Healthy
0.80% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($6.76) to ($7.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.58 out of 5 stars

Medical Sector

987th out of 1,080 stocks

Pharmaceutical Preparations Industry

481st out of 535 stocks

APVO stock logo

About Aptevo Therapeutics (NASDAQ:APVO) Stock

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Receive APVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APVO Stock News Headlines

Aptevo Therapeutics: Q4 Earnings Insights
Aptevo climbs as 2021 revenue more than doubles
See More Headlines
Receive APVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APVO Company Calendar

Last Earnings
8/11/2022
Today
9/24/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APVO
Employees
54
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.50
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+685.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-28,460,000.00
Net Margins
-222.55%
Pretax Margin
63.92%

Debt

Sales & Book Value

Annual Sales
$12.29 million
Book Value
$0.25 per share

Miscellaneous

Free Float
4,882,000
Market Cap
$15.88 million
Optionable
Optionable
Beta
5.84

Key Executives

  • Mr. Marvin L. White (Age 60)
    Pres, CEO & Director
    Comp: $870.65k
  • Mr. Jeffrey G. Lamothe CA (Age 56)
    Exec. VP & CFO
    Comp: $590.56k
  • Dr. Jane A. Gross Ph.D. (Age 65)
    Chief Scientific Officer
    Comp: $515.17k
  • Ms. SoYoung Kwon J.D.
    LL.M., Sr. VP, Gen. Counsel, Corp. Affairs & HR
  • Dr. Fatih M. Uckun M.D.
    Ph.D., Chief Clinical Advisor & Consultant
  • Dr. Dirk Huebner M.D. (Age 59)
    Chief Medical Officer













APVO Stock - Frequently Asked Questions

Should I buy or sell Aptevo Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APVO shares.
View APVO analyst ratings
or view top-rated stocks.

What is Aptevo Therapeutics' stock price forecast for 2022?

2 brokers have issued twelve-month price targets for Aptevo Therapeutics' shares. Their APVO share price forecasts range from $13.00 to $36.00. On average, they anticipate the company's stock price to reach $24.50 in the next year. This suggests a possible upside of 685.3% from the stock's current price.
View analysts price targets for APVO
or view top-rated stocks among Wall Street analysts.

How have APVO shares performed in 2022?

Aptevo Therapeutics' stock was trading at $7.87 on January 1st, 2022. Since then, APVO stock has decreased by 60.4% and is now trading at $3.12.
View the best growth stocks for 2022 here
.

When is Aptevo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our APVO earnings forecast
.

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc. (NASDAQ:APVO) issued its earnings results on Thursday, August, 11th. The biotechnology company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.33) by $0.53. Aptevo Therapeutics had a negative net margin of 222.55% and a negative trailing twelve-month return on equity of 481.02%.

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).

What is Aptevo Therapeutics' stock symbol?

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

Who are Aptevo Therapeutics' major shareholders?

Aptevo Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.40%), Virtu Financial LLC (0.25%), Franklin Resources Inc. (0.22%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Aptevo Therapeutics?

Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptevo Therapeutics' stock price today?

One share of APVO stock can currently be purchased for approximately $3.12.

How much money does Aptevo Therapeutics make?

Aptevo Therapeutics (NASDAQ:APVO) has a market capitalization of $15.88 million and generates $12.29 million in revenue each year.

How can I contact Aptevo Therapeutics?

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The official website for the company is www.aptevotherapeutics.com. The biotechnology company can be reached via phone at (206) 838-0500, via email at jurchisons@apvo.com, or via fax at 206-838-0503.

This page (NASDAQ:APVO) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.